We demonstrated that, in distinction to classical opioid receptors, ACKR3 doesn't trigger classical G protein signaling and is not modulated via the classical prescription or analgesic opioids, including morphine, fentanyl, or buprenorphine, or by nonselective opioid antagonists including naloxone. Alternatively, we set up that LIH383, an ACKR3-selective subnanomolar competitor https://charlesh495bsh9.techionblog.com/profile